{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-277","upperLimit":"194","value":"-35.5"},{"groupId":"OG001","lowerLimit":"-50","upperLimit":"503","value":"98"}]}],"title":"CD4+"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-734","upperLimit":"0","value":"-26"},{"groupId":"OG001","lowerLimit":"-61","upperLimit":"-9","value":"-24.5"}]}],"title":"CD19+"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-122","upperLimit":"104","value":"9"},{"groupId":"OG001","lowerLimit":"-287","upperLimit":"50","value":"-43"}]}],"title":"CD50"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"CD4+ and CD19+ are two key flow cytometry parameters, and total hemolytic complement (CD50) is a complement parameter. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.","dispersionType":"Full Range","groups":[{"description":"Participants received ofatumumab intravenously (IV) in Cycle 1 (defined as a treatment period of up to 4 weeks \\[Weeks (Wk.) 1 through 4\\]) (300 milligrams \\[mg\\] at Week 1 and 1000 mg at Weeks 2 through 4) and were followed up for 11 weeks (Weeks 5-16). After Week 16, during the Redosing Cycle (RC), participants who had Minor Response or stable disease after Cycle 1 and had not received another Waldenstrom's Macroglobulinemia (WM) therapy received 300 mg IV ofatumumab at Week 1 and 2000 mg IV ofatumumab at Weeks 2 through 5. Participants who achieved a response in either Cycle 1 or the RC and subsequently progressed before 36 months entered Cycle 2 of treatment and received IV ofatumumab 300 mg at Week 1 and IV ofatumumab 2000 mg during Weeks 2 through 5.","id":"OG000","title":"300 mg Ofatumumab, Wk. 1; 1000/2000 mg Ofatumumab, Wk. 2-4/2-5"},{"description":"Participants received ofatumumab IV at 300 mg at Week 1 and 2000 mg at Weeks 2 through 5 in Cycle 1 (defined as a treatment period of up to 5 weeks \\[Weeks 1 through 5\\]) and were followed up for 10 weeks (Weeks 6-16). After Week 16, during the RC, participants who had Minor Response or stable disease after Cycle 1 and had not received another WM therapy received 300 mg IV ofatumumab at Week 1 and 2000 mg IV ofatumumab at Weeks 2 through 5. Participants who achieved a response and subsequently progressed before 36 months entered Cycle 2 of treatment and received 300 mg at Week 1 and 2000 mg during Weeks 2 through 5.","id":"OG001","title":"300 mg Ofatumumab, Wk. 1; 2000 mg Ofatumumab, Wk. 2-5"}],"paramType":"MEDIAN","populationDescription":"ITT Population: only participants with blood count data at both Baseline and Month 3 were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Baseline and Month 3","title":"Change From Baseline in Blood Counts (CD4+, CD19+, CD50) at Month 3 After Treatment","type":"SECONDARY","unitOfMeasure":"cells per microliter (µL)"}